These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

118 related items for PubMed ID: 786676

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Double-blind evaluation of mazindol in refractory obesity.
    Smith RG, Innes JA, Munro JF.
    Br Med J; 1975 Aug 02; 3(5978):284. PubMed ID: 1097046
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. [Clinical evaluation of Teronac (mazindol) in the treatment of obesity in children. Part II. Anorectic properties and side effects (author's transl)].
    Gołebiowska M, Chlebna-Sokół D, Kobierska I, Konopińska A, Małek M, Mastalska A, Zwaigzne-Raczyńska J.
    Przegl Lek; 1981 Aug 02; 38(3):355-8. PubMed ID: 7017827
    [No Abstract] [Full Text] [Related]

  • 6. [Comparison of the anorectic effect of mazindol and placebo in obesity].
    Tatoń J, Czech A, Koliński P, Podwysocka G.
    Pol Tyg Lek; 1979 Dec 10; 34(50):1967-70. PubMed ID: 395517
    [No Abstract] [Full Text] [Related]

  • 7. Double-blind cross-over evaluation of mazindol in the treatment of obese hypertensive patients.
    Miach PJ, Thomson W, Doyle AE, Louis WJ.
    Med J Aust; 1976 Sep 04; 2(10):378-80. PubMed ID: 792640
    [Abstract] [Full Text] [Related]

  • 8. A double-blind trial of mazindol using a very low calorie formula diet.
    Baird IM, Howard AN.
    Int J Obes; 1977 Sep 04; 1(3):271-8. PubMed ID: 363631
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Three controlled trials of weight loss with phenylpropanolamine.
    Altschuler S, Conte A, Sebok M, Marlin RL, Winick C.
    Int J Obes; 1982 Sep 04; 6(6):549-56. PubMed ID: 6761288
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Mazindol in the control of micturition.
    Woodhouse CR, Tiptaft RC.
    Br J Urol; 1983 Dec 04; 55(6):636-8. PubMed ID: 6360295
    [Abstract] [Full Text] [Related]

  • 16. Subjective effects of two anorexigenic agents--fenfluramine and AN 448 in normal subjects.
    Holmstrand J, Jonsson J.
    Postgrad Med J; 1975 Dec 04; 51 Suppl 1():183-6. PubMed ID: 768967
    [No Abstract] [Full Text] [Related]

  • 17. Clinical and basic aspects of an anorexiant, mazindol, as an antiobesity agent in Japan.
    Inoue S, Egawa M, Satoh S, Saito M, Suzuki H, Kumahara Y, Abe M, Kumagai A, Goto Y, Shizume K.
    Am J Clin Nutr; 1992 Jan 04; 55(1 Suppl):199S-202S. PubMed ID: 1728834
    [Abstract] [Full Text] [Related]

  • 18. Double-blind comparison of placebo and 42-548, a new appetite suppressant, in obese volunteers.
    De Felice EA, Bronstein S, Cohen A.
    Curr Ther Res Clin Exp; 1969 May 04; 11(5):256-62. PubMed ID: 4977396
    [No Abstract] [Full Text] [Related]

  • 19. A multicentre study comparing mazindol and placebo in obese patients.
    Walker BR, Ballard IM, Gold JA.
    J Int Med Res; 1977 May 04; 5(2):85-90. PubMed ID: 326596
    [Abstract] [Full Text] [Related]

  • 20. Maziniol in the treatment of obesity.
    Sedgwick JP.
    Practitioner; 1975 Mar 04; 214(1281):418-20. PubMed ID: 1096123
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.